Consistent with prior findings in Kras-mutant DT6606 tumor models, VVL-DD achieved complete tumor regression in three out of seven mice and significantly prolonged survival compared to VVLΔTK (Figure 1C–E). This evidence concerns the gene KRAS and neoplasm.